Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
NCT01402284Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2011
- Primary completion
- Jul 2016
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoint: Number of Participants With Serious and Non-serious Adverse Events. Started Jul 2011; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01402284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01402284.